Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipah Vaccine (HenipaVax) Safety and Immunogenicity in Healthy Adults
NCT04199169Phase 1Completed
- Sponsor
- Auro Vaccines
- Start
- Feb 2020
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HenipaVax in Nipah virus infection (NiV) (9 arms), sponsored by Auro Vaccines. Primary endpoints: Rate of local and systemic solicited adverse events, Incidence of clinically significant abnormalities in clinical safety laboratory test results reported as unsolicited AEs and 2 more. Started Feb 2020; status: completed.
02
Drugs
HenipaVax
03
Conditions
Nipah virus infection (NiV)
Beyond the preview
Go deeper on NCT04199169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04199169.